Notícias e Atividades da Y-mAbs Therapeutics

Y-mAbs Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Y-mAbs Therapeutics é uma empresa listada sob o símbolo YMAB (US).

Veja o organograma con seus 16 executivos principais

Biografias mais buscadas da Y-mAbs Therapeutics

• Michael Rossi, President, Chief Executive Officer and Director
• Laura Hamill, Director
• Johan Wedell-Wedellsborg, Director

Recentes movimentos de executivos em Y-mAbs Therapeutics

• Sue Smith, Senior Vice President and Chief Commercial Officer, deixou a Companhia  (Notícia publicada em 13 de janeiro de 2025).
• Doug Gentilcore, ingressou na Companhia como Senior Vice President, Head of Danyelza Business Unit  (Notícia publicada em 13 de janeiro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Y-mAbs Therapeutics.

Y-mAbs Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).
• SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Y-mAbs Therapeutics

• Press Releases | Y-mAbs Therapeutics, Inc.
• Y-mAbs to Participate in Upcoming Investor Conferences in August | Y-mAbs Therapeutics, Inc.
• Press Releases | Y-mAbs Therapeutics, Inc.
• Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast | Y-mAbs Therapeutics, Inc.
• Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments | Y-mAbs Therapeutics, Inc.
• Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer | Y-mAbs Therapeutics, Inc.
• Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer | Y-mAbs Therapeutics, Inc.
• Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting | Y-mAbs Therapeutics, Inc.
• Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting | Y-mAbs Therapeutics, Inc.
• Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting | Y-mAbs Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Y-mAbs Therapeutics

• Y-mAbs Therapeutics na Wikipedia, Google News e Yahoo Finance
• Y-mAbs Therapeutics na LinkedIn, Twitter e YouTube